193 related articles for article (PubMed ID: 2537786)
1. Comparative study on a new one-stage clotting assay for heparin and its low molecular weight derivatives.
Harenberg J; Giese C; Knödler A; Zimmermann R
Haemostasis; 1989; 19(1):13-20. PubMed ID: 2537786
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
Harenberg J
J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
Harenberg J; Haaf B; Dempfle CE; Stehle G; Heene DL
Nephrol Dial Transplant; 1995; 10(2):217-22. PubMed ID: 7753456
[TBL] [Abstract][Full Text] [Related]
4. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin.
Harenberg J; Malsch R; Angelescu M; Lange C; Michaelis HC; Wolf H; Heene DL
Blood Coagul Fibrinolysis; 1996 Jun; 7(4):477-83. PubMed ID: 8840001
[TBL] [Abstract][Full Text] [Related]
6. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers.
Harenberg J; Giese C; Dempfle CE; Stehle G; Heene DL
Thromb Haemost; 1989 Jun; 61(3):357-62. PubMed ID: 2552604
[TBL] [Abstract][Full Text] [Related]
7. Effect of tissue factor pathway inhibitor (TFPI) in the HEPTEST assay and in an amidolytic anti factor Xa assay for LMW heparin.
Kristensen HI; Ostergaard PB; Nordfang O; Abildgaard U; Lindahl AK
Thromb Haemost; 1992 Sep; 68(3):310-4. PubMed ID: 1332210
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of heparin and low molecular weight heparin with capillary and venous whole blood.
Harenberg J; Giese C; Dempfle CE; Stehle G; Heene DL
Thromb Haemost; 1988 Dec; 60(3):377-81. PubMed ID: 2853458
[TBL] [Abstract][Full Text] [Related]
9. Laboratory monitoring of a low molecular weight heparin (enoxaparin) with a new clotting test (Heptest).
Bara L; Combe-Tamzali S; Conard J; Horellou MH; Samama M
Haemostasis; 1987; 17(3):127-33. PubMed ID: 3609913
[TBL] [Abstract][Full Text] [Related]
10. Laboratory monitoring of thromboprophylaxis with low molecular weight and standard heparin.
Vukovich T; Proidl S; Teufelsbauer H; Kautzky A; Erlacher L; Luger A; Weissel M
Thromb Res; 1992 Jun; 66(6):735-43. PubMed ID: 1519232
[TBL] [Abstract][Full Text] [Related]
11. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi.
Hellstern P; Bach J; Simon M; Saggau W
J Extra Corpor Technol; 2007 Jun; 39(2):81-6. PubMed ID: 17672188
[TBL] [Abstract][Full Text] [Related]
12. Monitoring therapy with LMW heparin: a comparison of three chromogenic substrate assays and the Heptest clotting assay.
Abildgaard U; Norrheim L; Larsen AE; Nesvold A; Sandset PM; Odegaard OR
Haemostasis; 1990; 20(4):193-203. PubMed ID: 2173672
[TBL] [Abstract][Full Text] [Related]
13. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of thrombin generation by heparin and LMW heparins: a comparison of chromogenic and clotting methods.
Houbouyan L; Padilla A; Gray E; Longstaff C; Barrowcliffe TW
Blood Coagul Fibrinolysis; 1996 Jan; 7(1):24-30. PubMed ID: 8845459
[TBL] [Abstract][Full Text] [Related]
15. Time-course of anti-Xa effects of calcium heparin and low-molecular-weight heparin given s.c.: insights for thrombosis prevention.
Romeo G; Salanitri G; Catania G
Drugs Exp Clin Res; 1988; 14(6):423-7. PubMed ID: 2850903
[TBL] [Abstract][Full Text] [Related]
16. HEPTEST: a suitable method for monitoring heparin during pregnancy.
Campbell PJ; Tirvengadum MA; Pickering W; Cohen H; Ryan KE
Clin Lab Haematol; 1999 Jun; 21(3):193-9. PubMed ID: 10448601
[TBL] [Abstract][Full Text] [Related]
17. Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma.
Dempfle CE; Zharkowa U; Elmas E; Ahmad-Nejad P; Neumaier M; Borggrefe M
Thromb Haemost; 2009 Nov; 102(5):1001-6. PubMed ID: 19888540
[TBL] [Abstract][Full Text] [Related]
18. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
Pindur G; Heiden M; Köhler M
Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of low molecular weight heparins.
Harenberg J
Semin Thromb Hemost; 1990 Oct; 16 Suppl():12-8. PubMed ID: 1962899
[TBL] [Abstract][Full Text] [Related]
20. Comparative human pharmacology of low molecular weight heparins.
Harenberg J; Stehle G; Augustin J; Zimmermann R
Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
